Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus W Brazier

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Antioxidants (Basel, Switzerland)|January 20, 2016
Antioxidant and Metal Chelation-Based Therapies in the Treatment of Prion DiseaseMarcus W Brazier, Anthony G Wedd, Steven J Collins
The European Journal of Neuroscience|December 13, 2006
Mouse galectin-1 inhibits the toxicity of glutamate by modifying NR1 NMDA receptor expressionTamuna Lekishvili, Shirley Hesketh, Marcus W Brazier, et al.
Therapeutic Delivery|May 8, 2013
Immunotherapeutic approaches in prion disease: progress, challenges and potential directionsMarcus W Brazier, Alexandra I Mot, Anthony R White, et al.
Free Radical Biology & Medicine|May 6, 2008
A manganese-superoxide dismutase/catalase mimetic extends survival in a mouse model of human prion diseaseMarcus W Brazier, Susan R Doctrow, Colin L Masters, et al.
Expert Review of Anti-Infective Therapy|July 23, 2009
Therapeutic interventions ameliorating prion diseaseMarcus W Brazier, Vanessa A Wall, Barry W Brazier, et al.
The FEBS Journal|August 31, 2006
High affinity copper binding by stefin B (cystatin B) and its role in the inhibition of amyloid fibrillationEva Zerovnik, Katja Skerget, Magda Tusek-Znidaric, et al.
The Journal of Biological Chemistry|March 12, 2008
Manganese binding to the prion proteinMarcus W Brazier, Paul Davies, Esmie Player, et al.
Expert Review of Neurotherapeutics|November 19, 2011
Metal attenuating therapies in neurodegenerative diseaseAlexandra I Mot, Anthony G Wedd, Layla Sinclair, et al.
Free Radical Biology & Medicine|December 13, 2006
Prion protein does not redox-silence Cu2+, but is a sacrificial quencher of hydroxyl radicalsRebecca C Nadal, Salama R Abdelraheim, Marcus W Brazier, et al.
Neurobiology of Disease|October 26, 2005
Extended period of asymptomatic prion disease after low dose inoculation: assessment of detection methods and implications for infection controlSteven J Collins, Victoria Lewis, Marcus W Brazier, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Antioxidants (Basel, Switzerland)|January 20, 2016
Antioxidant and Metal Chelation-Based Therapies in the Treatment of Prion DiseaseMarcus W Brazier, Anthony G Wedd, Steven J Collins
The European Journal of Neuroscience|December 13, 2006
Mouse galectin-1 inhibits the toxicity of glutamate by modifying NR1 NMDA receptor expressionTamuna Lekishvili, Shirley Hesketh, Marcus W Brazier, et al.
Therapeutic Delivery|May 8, 2013
Immunotherapeutic approaches in prion disease: progress, challenges and potential directionsMarcus W Brazier, Alexandra I Mot, Anthony R White, et al.
Free Radical Biology & Medicine|May 6, 2008
A manganese-superoxide dismutase/catalase mimetic extends survival in a mouse model of human prion diseaseMarcus W Brazier, Susan R Doctrow, Colin L Masters, et al.
Expert Review of Anti-Infective Therapy|July 23, 2009
Therapeutic interventions ameliorating prion diseaseMarcus W Brazier, Vanessa A Wall, Barry W Brazier, et al.
The FEBS Journal|August 31, 2006
High affinity copper binding by stefin B (cystatin B) and its role in the inhibition of amyloid fibrillationEva Zerovnik, Katja Skerget, Magda Tusek-Znidaric, et al.
The Journal of Biological Chemistry|March 12, 2008
Manganese binding to the prion proteinMarcus W Brazier, Paul Davies, Esmie Player, et al.
Expert Review of Neurotherapeutics|November 19, 2011
Metal attenuating therapies in neurodegenerative diseaseAlexandra I Mot, Anthony G Wedd, Layla Sinclair, et al.
Free Radical Biology & Medicine|December 13, 2006
Prion protein does not redox-silence Cu2+, but is a sacrificial quencher of hydroxyl radicalsRebecca C Nadal, Salama R Abdelraheim, Marcus W Brazier, et al.
Neurobiology of Disease|October 26, 2005
Extended period of asymptomatic prion disease after low dose inoculation: assessment of detection methods and implications for infection controlSteven J Collins, Victoria Lewis, Marcus W Brazier, et al.
Pageof 2